Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
During the fighting near Izyum in the spring of 2022, military Mikhail Yurchuk received a complex wound. As a result, the man lost an arm and a leg. First, he was fitted with a prosthetic leg, and recently at the Lviv National Rehabilitation Center "Indestructible" - a modern bionic prosthetic arm. Thanks to special sensors, it can reproduce familiar movements. Now the warrior is undergoing rehabilitation. This was reported in the First TMO Lviv.
Отдельной проблемой является лечение АГ у больных COVID-19. Наличие в анамнезе АГ у пациентов с COVID-19 ассоциировалось с более тяжелым течением инфекции в отличие от больных, у которых гипертензия отсутствовала. По современным представлениям в период пандемии COVID-19 больные АГ должны тщательнее следить за уровнем своего АД и принимать постоянно рекомендованные врачом препараты. Это касается и применения для лечения больных АГ так называемых блокаторов ренин-ангиотензиновой системы: ингибиторов ангиотензин-превращающего фермента и блокаторов рецепторов ангиотензина II. Целый ряд проведенных в последнее время исследований, что указанные группы препаратов не только не повышают риск инфицирования вирусом, но и достоверно улучшают течение коронавирусной болезни.
The current COVID-19 pandemic caused by SARS-CoV-2 has become a global health emergency. Treatment of chronic inflammatory bowel disease (CIBD) according to the standards includes the use of 5-aminosalicylic acid (5-ASA), corticosteroids, cytostatics, and biological therapy. However, these treatments can weaken the immune system, which potentially puts COPD patients at increased risk of infections and infectious diseases, including COVID-19. Therefore, patients with CVD have a greater risk of developing COVID-19 and more severe clinical course, or even death, compared to the general population.
The use of thiopurine (azathioprine and mercaptopurine) reduces the immune response to viruses, which is associated with an increased risk of opportunistic infections. There is limited evidence that they increase the risk of respiratory infections. The risks and benefits should be considered, but most patients can continue on a stable dose. In patients in stable remission, elderly patients and in the presence of concomitant pathology, it is recommended to stop taking thiopurine. During a pandemic, it is recommended to avoid starting thiopurine or increasing the dose, which will allow patients to avoid potential side effects. If the patient is in contact with a COVID-19 person, temporary withdrawal of thiopurine for 2 weeks should be considered. If a patient tests positive for SARS-CoV-2 and/or develops COVID-19, temporary discontinuation of thiopurine may be recommended until the patient clears the infection.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием